HALO
HEALTHCAREHalozyme Therapeutics Inc
$66.35+0.48 (+0.73%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving HALO Today?
No stock-specific AI insight has been generated for HALO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$47.50$82.22
$66.35
Fundamentals
Market Cap$7.9B
P/E Ratio25.9
EPS$2.56
Dividend Yield—
Dividend / Share—
ROE1.5%
Profit Margin0.2%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding118.5M
HALO News
20 articles- ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·May 8, 2026
- Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology TargetsYahoo Finance·May 7, 2026
- ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresYahoo Finance·May 6, 2026
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyYahoo Finance·May 6, 2026
- Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 GuidanceMarketbeat·May 6, 2026
- Halozyme (HALO) Rated Buy on Strong Royalty GrowthYahoo Finance·May 2, 2026
- How Investors Are Reacting To Halozyme Therapeutics (HALO) Hiring Big-Pharma Veteran Darren Snellgrove As CFOYahoo Finance·May 2, 2026
- How The Halozyme (HALO) Story Is Shifting Around Royalties Partnerships And Execution RiskYahoo Finance·May 2, 2026
- Halozyme to Report First Quarter 2026 Financial and Operating ResultsYahoo Finance·Apr 30, 2026
- Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance·Apr 30, 2026
- Halozyme Appoints Darren Snellgrove as Chief Financial OfficerYahoo Finance·Apr 30, 2026
- Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 28, 2026
- Is Halozyme Therapeutics (HALO) Offering Value After Mixed Multi Year Share Price PerformanceYahoo Finance·Apr 22, 2026
- 1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That UnderwhelmYahoo Finance·Apr 21, 2026
- Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?Yahoo Finance·Apr 20, 2026
- Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 15, 2026
- Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Funds ("ETFs")Yahoo Finance·Apr 14, 2026
- 3 Cash-Producing Stocks with Exciting PotentialYahoo Finance·Apr 10, 2026
- Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative?Yahoo Finance·Apr 10, 2026
All 20 articles loaded
Price Data
Open$66.80
Previous Close$65.87
Day High$67.29
Day Low$65.64
52 Week High$82.22
52 Week Low$47.50
52-Week Range
$47.50$82.22
$66.35
Fundamentals
Market Cap$7.9B
P/E Ratio25.9
EPS$2.56
Dividend Yield—
Dividend / Share—
ROE1.5%
Profit Margin0.2%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding118.5M
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—